Wednesday, June 8, 2011 - 08:53
For too long, viral hepatitis, an epidemic that doesn't necessarily make headlines, has steadily and silently affected the lives of millions of Americans. In fact, as many as 5.3 million Americans have hepatitis B or hepatitis C, contributing to a global burden that now engulfs more than half a billion people....
Monday, May 23, 2011 - 11:53
The U.S. Food and Drug Administration today approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.
Monday, May 23, 2011 - 11:47
The U.S. Food and Drug Administration today approved Victrelis (boceprevir) to treat certain adults with chronic hepatitis C. Victrelis is used for patients who still have some liver function, and who either have not been previously treated with drug therapy for their hepatitis C or who have failed such treatment. Victrelis is approved for use in combination with peginterferon alfa and ribavirin.
Friday, May 20, 2011 - 21:03
The Food and Drug Administration (FDA) invites you to participate in a teleconference briefing to discuss two Direct Acting Antivirals (DAAs) for the treatment of hepatitis C, boceprevir and telaprevir, that were discussed at an April 27 -28, 2011 meeting of the FDA Antiviral Drugs Advisory Committee.
Thursday, May 19, 2011 - 20:02
Twenty Members of Congress, led by Representatives Hank Johnson (D-GA) and Judy Chu (D-CA) submitted a letter to the House Appropriations Committee and the Subcommittee on Labor, Health and Human Services requesting funding for at least the President’s increase of $5.2 million for hepatitis prevention in FY2012
Saturday, April 30, 2011 - 10:50
NVHR Director Speaks at FDA Hepatitis C Drug Hearing
Thursday, April 28, 2011 - 08:00